Program
Cetuximab
Also written as “cetuximab”, “RPH-002” and “Cetuximab + Irinotecan”.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Neoplasms, led by 26 companies.
Drug pageCetuximab: every studyMany companies study it; this page follows only the 90 they lead. All 565 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 300 open or running | phase 3since Jun 4, 2003 | Apr 30, 2002 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 170 open or running | phase 3since Sep 7, 2005 | Jul 28, 2005 | none ahead |
| Pfizerits history only | 53 open or running | phase 3since Oct 5, 2020 | Dec 1, 2010 | Dec 31, 2029phase 2 · NCT05226871 |
| Bristol-Myers Squibbits history only | 40 open or running | phase 3since Nov 17, 2017 | Jan 7, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 41 open or running | phase 2since Dec 18, 2007 | Jul 3, 2007 | Aug 31, 2030phase 1 · NCT04929223 |
| R-Pharmits history only | 40 open or running | phase 3since Feb 20, 2026 | Sep 28, 2006 | none ahead |
| Sarah Cannon Research Instituteits history only | 41 open or running | phase 3since Nov 9, 2005 | Nov 2, 2005 | none ahead |
| Merckits history only | 22 open or running | phase 3since May 21, 2025 | May 21, 2025 | Mar 28, 2029phase 3 · NCT06997497 |
| Novartisits history only | 20 open or running | phase 2since May 16, 2012 | May 24, 2007 | none ahead |
| Pierre Fabreits history only | 20 open or running | phase 2since Sep 17, 2018 | Sep 17, 2018 | none ahead |
| Bayerits history only | 10 open or running | phase 1since Oct 28, 2013 | Oct 28, 2013 | none ahead |
| BOE Technology Groupits history only | 11 open or running | phase 2since Apr 10, 2026 | Apr 10, 2026 | Apr 2028phase 2 · NCT07551778 |
| Boehringer Ingelheimits history only | 10 open or running | phase 1since Dec 19, 2013 | Dec 19, 2013 | none ahead |
| Bonecaits history only | 10 open or running | phase 2since Jun 21, 2009 | Jun 21, 2009 | none ahead |
| Cinnagenits history only | 11 open or running | phase 3since Dec 31, 2017 | Dec 31, 2017 | none ahead |
| Daiichi Sankyoits history only | 10 open or running | phase 1since Jan 19, 2015 | Jan 19, 2015 | none ahead |
| Fosun Pharmaits history only | 11 open or running | phase 1since Apr 7, 2026 | Apr 7, 2026 | Jun 30, 2027phase 1 · NCT07543471 |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Oct 5, 2007 | Oct 5, 2007 | none ahead |
| Haisco Pharmaceutical Groupits history only | 11 open or running | phase 2since Aug 13, 2026 | Aug 13, 2026 | Sep 30, 2029phase 2 · NCT07790510 |
| Harrison Clinical Researchits history only | 10 open or running | phase 1since Jan 9, 2009 | Jan 9, 2009 | none ahead |
| Innate Pharmaits history only | 10 open or running | phase 2since Dec 17, 2015 | Dec 17, 2015 | none ahead |
| IntegraGenits history only | 10 open or running | phase 3since Nov 24, 2017 | Nov 24, 2017 | none ahead |
| Merrimack Pharmaceuticalsits history only | 10 open or running | phase 1since Oct 7, 2011 | Oct 7, 2011 | none ahead |
| Revolution Medicinesits history only | 11 open or running | phase 2since May 20, 2024 | May 20, 2024 | Sep 30, 2028phase 2 · NCT06445062 |
| Shanghai Celfuture Biotechits history only | 10 open or running | phase 2since Jan 4, 2023 | Jan 4, 2023 | none ahead |
| Verastemits history only | 11 open or running | phase 2since Jun 15, 2026 | Jun 15, 2026 | Jun 2027phase 2 · NCT07659795 |
Also a collaborator on its studies: Ono Pharmaceutical, AstraZeneca, Prologue Research International, Sanofi and Merck, S.L., Spain.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Apr 30, 2002.
- May 6, 2005Phase 1 study in NeoplasmsNCT00110357 · 48 enrolled · United States
- Jun 1, 2005Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00112346 · 120 enrolled · United States, Canada
- Jun 1, 2005Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00112294 · 755 enrolled · United States
- Sep 9, 20054 phase 1 studiesNCT00162318, NCT00207155, NCT00207116 and 1 more
- Sep 9, 2005Phase 2 study in Mucinous Gastrointestinal AdenocarcinomaNCT00162110 · 40 enrolled · United States
- Jun 20, 2006Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00343291 · 121 enrolled · United States
- Aug 8, 2006Phase 2 study in Colorectal NeoplasmsNCT00362102 · 38 enrolled
- Jun 16, 2008Phase 2 study in Advanced CancerNCT00698841 · 79 enrolled · United States, Puerto Rico
- Oct 6, 2008Phase 2 study in Lung NeoplasmsNCT00768131 · United States
- Mar 20, 2009Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00867009 · 113 enrolled · Austria, Germany, Greece and more
- Jan 20, 2010Phase 2 study in Head and Neck NeoplasmsNCT01057589 · 66 enrolled · Belgium, France, Germany and more
- Feb 3, 2010Phase 2 study in Head and Neck NeoplasmsNCT01063075 · 34 enrolled · United States, Canada
- Mar 3, 20103 phase 2 studies in Head and Neck NeoplasmsNCT01081041, NCT01087970, NCT01099358
- Apr 22, 2010Phase 2 study in Lung NeoplasmsNCT01109524 · 72 enrolled · United States, Canada, Puerto Rico
- Dec 9, 2018Named cetuximabINNProposed as its International Nonproprietary Name in WHO's List 120 · before, RPH-002
TargetBeta
“A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 30 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01109524Lung Neoplasms · United States, Canada, Puerto Rico | 2 | Completed | Sep 2012 | 72 |
| NCT01099358Head and Neck Neoplasms · United States, Canada | 2 | Completed | Oct 2015 | 47 |
| NCT01087970Head and Neck Neoplasms · United States | 2 | Completed | Aug 2013 | 69 |
| NCT01081041Head and Neck Neoplasms · United States, Canada, Mexico | 2 | Completed | Aug 2013 | 187 |
| NCT01063075Head and Neck Neoplasms · United States, Canada | 2 | Completed | May 2015 | 34 |
| NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more | 2 | Completed | Feb 2012 | 66 |
| NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more | 2 | Completed | May 2011 | 113 |
| NCT00768131Lung Neoplasms · United States | 2 | Withdrawn | Oct 2008 | 0 |
| NCT00698841Advanced Cancer · United States, Puerto Rico | 2 | Completed | Feb 2010 | 79 |
| NCT00362102Colorectal Neoplasms | 2 | Completed | Jul 2006 | 38 |
| NCT00343291Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | May 2010 | 121 |
| NCT00207155Colorectal Neoplasms · United States, Canada, Spain | 1 | Completed | Feb 2006 | 110 |
| NCT00207116Carcinoma, Non-Small-Cell Lung · United States | 1 | Completed | Mar 2006 | 120 |
| NCT00207077Neoplasms · United States | 1 | Completed | May 2007 | 33 |
| NCT00162318Carcinoma, Non-Small-Cell Lung · United States | 1 | Completed | Apr 2006 | 30 |
| NCT00162110Mucinous Gastrointestinal Adenocarcinoma · United States | 2 | Completed | Jan 2007 | 40 |
| NCT00112346Carcinoma, Non-Small-Cell Lung · United States, Canada | 2 | Completed | Dec 2006 | 120 |
| NCT00112294Carcinoma, Non-Small-Cell Lung · United States | 3 | Completed | Apr 2007 | 755 |
| NCT00110357Neoplasms · United States | 1 | Completed | Mar 2008 | 48 |
| NCT00097227Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Apr 2007 | 165 |
| NCT00097214Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Apr 2007 | 57 |
| NCT00095199Carcinoma, Non-Small-Cell Lung · United States, Canada | 3 | Completed | Jul 2011 | 939 |
| NCT00083720Colorectal Neoplasms · United States, Canada | 2 | Completed | Apr 2008 | 87 |
| NCT00082212Ovarian Neoplasms · United States | 2 | Terminated | Jun 2007 | 25 |
| NCT00063388Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Jun 2005 | 66 |
| NCT00063141Colorectal Neoplasms · United States, Australia, Austria and more | 3 | Completed | Jun 2006 | 1,302 |
| NCT00061815Colorectal Neoplasms · United States | 3 | Completed | Dec 2004 | 102 |
| NCT00055419Colorectal Neoplasms · United States | 2 | Completed | Jul 2004 | 744 |
| NCT00044863Colorectal Neoplasms · United States | 2 | Completed | Dec 2005 | 250 |
| NCT00034541Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | May 2003 | 32 |
How it is read
Names in the registry
- “Cetuximab”, 57 entries
- “cetuximab”, 11 entries
- “RPH-002”, 2 entries
- “Cetuximab + Irinotecan”, 2 entries
- “Cetuximab + mFOLFOX6”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 34 studies
- Carcinoma, Non-Small-Cell Lung, 17 studies
- Squamous Cell Carcinoma of Head and Neck, 10 studies
- Head and Neck Neoplasms, 7 studies
- Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.